New clinical trial boosts case for using MDMA, or ecstasy, to treat severe PTSD

MDMA or Ecstasy
(Image credit: Adek Berry/AFP/Getty Images)

A Phase 3 clinical trial of 90 people with severe post-traumatic stress disorder (PTSD) found that combining MDMA, the illegal psychedelic drug also known as ecstasy or Molly, with talk therapy significantly relieved symptoms, The New York Times reports. Two months after participating in the trial, 67 percent of the combat veterans, first responders, and survivors of sexual assault, childhood trauma, mass shootings, and domestic violence who were given MDMA no longer qualified for a PTSD diagnosis, versus 32 percent given a placebo with their talk therapy.

The study, awaiting likely publication in the journal Nature Medicine later this month, found no serious adverse reactions from the clinical doses of MDMA. If a second Phase 3 trial underway with 100 subjects shows similarly promising results and safety, the Food and Drug Administration could approve MDMA-assisted therapy for therapeutic use as soon as 2023, the Times reports.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.